Prodessa Pharmaceuticals
About
Prodessa Pharmaceuticals is a Stockholm-based animal health company, founded in 2025 by researchers from the Karolinska Institutet, Sweden, and SUNY Upstate New York, USA. We are driven by our mission, that through dedication, innovation and cutting-edge research, be on the frontier in the fight against pet obesity.
Our flagship molecule, K161, a pan-SHIP1/2 inhibitor, reduces chronic inflammation and improves oxidative metabolism to promote leanness and preserve muscle mass. In preclinical small animal trials, K161 achieved a 20–25% weight reduction without appetite suppression, change in diet or enhanced physical activity.
We are now looking for partners to join our journey.
Areas of Activity
Representatives
Prodessa Pharmaceuticals